Download PDF
Thromb Haemost 2011; 105(03): 568-569
DOI: 10.1160/TH10-07-0495
Letter to the Editor
Schattauer GmbH

Heparin-induced thrombocytopenia: Successful biological and clinical management with lepirudin despite severe renal impairment

Céline Desconclois
1   Service d’Hématologie Biologique, hôpital Bicêtre, AP-HP, Université Paris Sud, Le Kremlin Bicêtre, France
,
Catherine Ract
2   Service de Réanimation Chirurgicale, hôpital Bicêtre, AP-HP, Université Paris Sud, Le Kremlin Bicêtre, France
,
Tewfik Boutekedjiret
1   Service d’Hématologie Biologique, hôpital Bicêtre, AP-HP, Université Paris Sud, Le Kremlin Bicêtre, France
,
Martine Alhenc-Gelas
3   Service d’Hématologie Biologique, Hôpital Européen Georges Pompidou AP-HP, Paris, France
,
Jacques Duranteau
2   Service de Réanimation Chirurgicale, hôpital Bicêtre, AP-HP, Université Paris Sud, Le Kremlin Bicêtre, France
,
Marie Dreyfus
1   Service d’Hématologie Biologique, hôpital Bicêtre, AP-HP, Université Paris Sud, Le Kremlin Bicêtre, France
,
Valerie Proulle
1   Service d’Hématologie Biologique, hôpital Bicêtre, AP-HP, Université Paris Sud, Le Kremlin Bicêtre, France
› Author Affiliations
Further Information

Publication History

Received: 29 July 2010

Accepted after major revision: 25 January 2010

Publication Date:
27 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Warkentin TE, Levine MN, Hirsh J. et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
    CrossrefPubMedGoogle Scholar
  • 2 Wallis DE, Workman DL, Lewis BE. et al. Failure of early heparin cessation as treatment for heparin-in-duced thrombocytopenia. Am J Med 1999; 106: 629-635.
    CrossrefPubMedGoogle Scholar
  • 3 Nowak G. Heparin-induced thrombocytopenia (HIT II) – A drug associated autoimmune disease. Thromb Haemost 2009; 102: 887-891.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006; 95: 967-981.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Tardy-Poncet B, Wolf M, Lasne D. et al. Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases. Intensive Care Med 2009; 35: 1449-1453.
    CrossrefPubMedGoogle Scholar
  • 6 Warkentin TE, Greinacher A, Koster A. et al. American College of Chest Physicians.. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S-380S.
    CrossrefPubMedGoogle Scholar
  • 7 Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008; 99: 819-829.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Lubenow N, Eichler P, Lietz T. et al. Hit Investigators Group.. Lepirudin in patients with heparin-induced thrombocytopenia – results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005; 3: 2428-2436.
    CrossrefPubMedGoogle Scholar